Navigation Links
Fate Therapeutics Closes $30 Million Series B Financing
Date:11/16/2009

LA JOLLA, Calif., Nov. 16 /PRNewswire/ -- Fate Therapeutics, Inc. announced today that it has completed a $30 million Series B financing led by OVP Venture Partners. Joining OVP Venture Partners in the financing is a syndicate of corporate investors, including Astellas Venture Management, Genzyme Ventures and a third undisclosed corporate investor. The three co-leaders of the Company's Series A financing, ARCH Venture Partners, Polaris Venture Partners and Venrock, also participated in the latest round of financing. In conjunction with the funding, Carl Weissman, managing director at OVP Venture Partners, joined the Company's board of directors.

"Fate Therapeutics has made rapid progress in advancing its pipeline of Stem Cell Modulators and in establishing the leading industrialized platform for induced pluripotent stem cell technology," said Mr. Weissman. "We are confident that the Company's management team and its scientists will continue to identify novel mechanisms to selectively intervene in adult stem cell biology for medicine, and we believe its expert knowledge, innovative approach and advanced technologies in modulating cell fate can be leveraged across a broad therapeutic spectrum of drug discovery and development opportunities."

"The leadership of OVP, the continued support of our top-tier existing investors, and the breadth of drug development and commercialization expertise of our corporate investor syndicate creates a powerful foundation for the expansion of our stem cell biology discovery engine," said Paul Grayson, president and CEO of Fate Therapeutics. "Target populations of adult stem cells must be exquisitely characterized and quantitated, and we are employing genomic, proteomic and epigenetic expression technologies to identify cell-specific biological mechanisms to modulate cell fate for diseases that currently have limited to no tre
'/>"/>

SOURCE Fate Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cornerstone Therapeutics to Present at the 6th Annual Lazard Capital Markets Healthcare Conference
2. Esperion Therapeutics Initiates Phase I Clinical Study for ETC-1002
3. Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA
4. Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
5. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
6. Nektar Therapeutics Reports Third Quarter 2009 Financial Results
7. Tolera Therapeutics Files IND Application for TOL101, Appoints OToole to Lead Clinical Operations
8. Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates
9. Cell Therapeutics, Inc.s (CTI) Presentation at BIO Investor Forum to be Webcast
10. Oxygen Biotherapeutics, Inc. Expands Board of Directors
11. Cornerstone Therapeutics to Host Third Quarter 2009 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... 24, 2014  IGI Laboratories, Inc. (NYSE MKT: IG), ... generic pharmaceutical company, today announced it has submitted an ... Food and Drug Administration (FDA), which brings the Company,s ... with eighteen submissions now pending at the FDA. ... of the Company, commented, "Our team here at IGI ...
(Date:11/24/2014)... Nov. 24, 2014  Last week, Representatives ... (D-NC) took a bold bipartisan step on ... the OPEN Act. Original co-sponsors of the legislation ... Act will incentivize drug makers and innovators to ... and pediatric cancers, which opens the door to ...
(Date:11/24/2014)...   First published articles now available ... , a world-leading provider of scientific, technical and medical information ... the latest title in the Current Opinion journal series ... . Current Opinion in Food ... keep up-to-date with the expanding volume of information published in ...
(Date:11/24/2014)... 23, 2014 One of the most extensive, ... and photonics is now available to high school and junior ... SPIE, the international society for optics and photonics , ... SPIE Digital Library available to high schools for ... technologies are integral to all areas of life in today’s ...
Breaking Biology Technology:IGI Laboratories, Inc. Announces ANDA Submission 2OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 3SPIE Digital Library Now Available to High Schools, Two-Year Colleges at No or Low Cost 2
... , HOUSTON, Nov. 12 An experiment by college students ... to orbit aboard space shuttle Atlantis. , (Logo: ... at Texas Southern University in Houston developed the experiment that ... is scheduled to launch at 2:28 p.m. EST on Nov. ...
... Reportlinker.com announces that a new market research ... Diclofenac sodium (CAS 15307-79-6) Market ... http://www.reportlinker.com/p0163683/Diclofenac-sodium-(CAS-15307-79-6)-Market-Research-Report-2009.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire ... (CAS 15307-79-6) Market Research Report 2009, presents ...
... BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced that ... with part of the proceeds from the $300 million securitization ... of PDL on December 1, 2009 will be paid a ... significant amount of convertible securities outstanding, the amount of the ...
Cached Biology Technology:Students Send Microbe Experiment on Space Shuttle Atlantis 2Students Send Microbe Experiment on Space Shuttle Atlantis 3Reportlinker Adds Diclofenac sodium (CAS 15307-79-6) Market Research Report 2009 2PDL BioPharma Announces Special Dividend Payment 2
(Date:11/15/2014)... Nov. 13, 2014  While we may still be a ... used in "Star Trek" to gain instant access to all ... work with smartphones and tablets for monitoring and measuring our ... world. This may seem a tad Orwellian to some, but ... some of these technological opportunities into their healthcare regime. ...
(Date:11/10/2014)... detergent pods began appearing on U.S. store shelves in ... numbers ever since. The small packets can be tossed ... out a liquid or powder. The convenience, though, has ... study from researchers at Nationwide Children,s Hospital found that ... reports of 17,230 children younger than 6 years of ...
(Date:11/7/2014)... 2014 Leading Biometric companies aim to ... revolutionizing online transactions.  Companies in focus today are: NXT-ID, Inc. ... BABA ), Google Inc. (NASDAQ: GOOG ), ... EBAY ) and MasterCard Inc. (NYSE: MA) ... a biometric authentication company focused on the growing mobile commerce ...
Breaking Biology News(10 mins):Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Study finds laundry detergent pods, serious poisoning risk for children 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6
... shows motion and door sensors placed in elders' homes ... memory changes that are early signs of dementia. , ... International Conference on Alzheimer's Disease and Related Disorders in ... may be a reliable way of assessing changes in ...
... single protein can turn on and off a key component ... genomic dance, said researchers at the University of Southern California ... arthritis, allergies and dozens of other illnesses ?begin when the ... on-off mechanism for the immune system has been the subject ...
... component of the immune system, a line of genetically engineered ... University School of Medicine in St. Louis have found. ... missing immune system component, a group of molecules known as ... unrecognized backup that is similar enough to step in and ...
Cached Biology News:In-home sensors spot dementia signs in elderly 2In-home sensors spot dementia signs in elderly 3Flick of a protein switches immune response 2Mice lacking key immune component still control chronic viral infections 2Mice lacking key immune component still control chronic viral infections 3
Anti-human Carcinoma Associated Antigen, Clone 115D8, Monoclonal Antibody Innate Immunity - Tumor Markers...
Ezrin/Radixin/Moesin Antibody...
Rabbit anti-NFkB p105/p50 (Ser529) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Rabbit Anti-conjugated Agmatine Polyclonal Antibody...
Biology Products: